Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Oncology trial design is getting a major overhaul. At an OncLive workshop, experts from academia, industry, and the FDA broke down how Project Optimus is reshaping dose selection, what it really takes to earn breakthrough therapy designation, and why patient selection can make or break a trial. The old "maximum tolerated dose" playbook is out — smarter, model-based approaches are in.
Oncology drug development is evolving fast, and the decisions made in early-phase trial design can determine whether a promising therapy ever reaches patients. At a recent OncLive Scientific Interchange and Workshop, fellows from four academic programs worked alongside faculty from academia, industry, biostatistics, and the FDA to simulate the development of two assets: a brain-penetrant EGFR × MET bispecific antibody and a HER2-directed antibody-drug conjugate (ADC) for NSCLC.
The biggest theme? The old maximum tolerated dose (MTD) paradigm is out. Under the FDA's Project Optimus framework — finalized in August 2024 — model-based designs that jointly assess safety and efficacy are now the standard. Faculty also stressed that breakthrough therapy designation requires demonstrating meaningful improvement over the best available therapy, not just a handful of responses in a small, wide-confidence-interval dataset. And when it comes to patient selection, mandatory biopsies and tight biomarker criteria can torpedo accrual even if the science is sound.
Key Takeaways:
Why it matters: As novel agents like bispecific antibodies and ADCs flood the NSCLC pipeline, getting trial design right from the start is critical — not just for regulatory success, but for ensuring the right patients benefit from the right doses.